Live Breaking News & Updates on Diamedica therapeutics company profile

Stay updated with breaking news from Diamedica therapeutics company profile. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

DiaMedica Therapeutics (DMAC) to Release Earnings on Wednesday

DiaMedica Therapeutics (DMAC) to Release Earnings on Wednesday
themarketsdaily.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from themarketsdaily.com Daily Mail and Mail on Sunday newspapers.

Craig-hallum , Diamedica-therapeutics-company-profile , Nasdaq , Diamedica-therapeutics-inc , Diamedica-therapeutics , Get-free-report , Medica-therapeutics , Medica-therapeutics-inc , Diamedica-therapeutics-daily ,

DiaMedica Therapeutics (NASDAQ:DMAC) Stock Price Down 8.6%

DiaMedica Therapeutics Inc. (NASDAQ:DMAC – Get Free Report) shares fell 8.6% on Monday . The company traded as low as $2.50 and last traded at $2.56. 183,312 shares changed hands during trading, an increase of 113% from the average session volume of 85,998 shares. The stock had previously closed at $2.80. Wall Street Analyst Weigh […]

Diamedica-therapeutics-company-profile , Renaissance-technologies , Citadel-advisors , Dimensional-fund-advisors , Nasdaq , Diamedica-therapeutics-inc , Diamedica-therapeutics , Get-free-report , Medica-therapeutics , Fund-advisors , Street-corp

Insider Buying: DiaMedica Therapeutics Inc. (NASDAQ:DMAC) Major Shareholder Acquires $4,999,999.20 in Stock

DiaMedica Therapeutics Inc. (NASDAQ:DMAC – Free Report) major shareholder Koch Thomas Von bought 1,470,588 shares of DiaMedica Therapeutics stock in a transaction on Friday, June 23rd. The shares were acquired at an average price of $3.40 per share, for a total transaction of $4,999,999.20. Following the completion of the acquisition, the insider now owns 4,326,435 […]

Diamedica-therapeutics-inc , Securities-exchange-commission , Nasdaq , Citadel-advisors , Catalyst-financial-partners , Renaissance-technologies , Diamedica-therapeutics-company-profile , Diamedica-therapeutics , Free-report , Koch-thomas-von , Exchange-commission

DiaMedica Therapeutics Inc. (NASDAQ:DMAC) Director Purchases $254,150.00 in Stock

DiaMedica Therapeutics Inc. (NASDAQ:DMAC – Get Rating) Director Randall Michael Giuffre acquired 65,000 shares of DiaMedica Therapeutics stock in a transaction that occurred on Friday, June 23rd. The shares were bought at an average price of $3.91 per share, with a total value of $254,150.00. Following the transaction, the director now directly owns 360,355 shares […]

Randall-michael-giuffre , Diamedica-therapeutics-company-profile , Renaissance-technologies , Dimensional-fund-advisors , Nasdaq , Catalyst-financial-partners , Diamedica-therapeutics-inc , Citadel-advisors , Diamedica-therapeutics , Get-rating , Director-randall-michael-giuffre , Medica-therapeutics

Insider Buying: DiaMedica Therapeutics Inc. (NASDAQ:DMAC) Insider Buys 38,364 Shares of Stock

DiaMedica Therapeutics Inc. (NASDAQ:DMAC – Get Rating) insider David J. Wambeke purchased 38,364 shares of the stock in a transaction on Friday, June 23rd. The stock was acquired at an average cost of $3.91 per share, with a total value of $150,003.24. Following the acquisition, the insider now owns 507,114 shares of the company’s stock, […]

Davidj-wambeke , Diamedica-therapeutics-company-profile , Renaissance-technologies , Securities-exchange-commission , Diamedica-therapeutics-inc , Nasdaq , Dimensional-fund-advisors , Citadel-advisors , Diamedica-therapeutics , Get-rating , Exchange-commission

DiaMedica Therapeutics (NASDAQ:DMAC) Stock Rating Upgraded by Oppenheimer

DiaMedica Therapeutics (NASDAQ:DMAC – Get Rating) was upgraded by analysts at Oppenheimer from a “market perform” rating to an “outperform” rating in a report released on Thursday, The Fly reports. The brokerage currently has a $7.00 target price on the stock. Oppenheimer’s price target points to a potential upside of 64.71% from the company’s previous […]

Davidj-wambeke , Renaissance-technologies , Diamedica-therapeutics-inc , Diamedica-therapeutics-company-profile , Dimensional-fund-advisors , Securities-exchange-commission , Catalyst-financial-partners , Citadel-advisors , Diamedica-therapeutics , Get-rating , Medica-therapeutics

DiaMedica Therapeutics (OTCMKTS:DMCAF) Trading 2.5% Higher

Shares of DiaMedica Therapeutics Inc. (OTCMKTS:DMCAF – Get Rating) traded up 2.5% during mid-day trading on Friday . The company traded as high as $1.63 and last traded at $1.63. 20,100 shares were traded during mid-day trading, a decline of 85% from the average session volume of 131,151 shares. The stock had previously closed at […]

Diamedica-therapeutics-company-profile , Diamedica-therapeutics-inc , Diamedica-therapeutics , Get-rating , Medica-therapeutics-inc , Diamedica-therapeutics-daily , Otcmkts-dmcaf , Dmcaf , Medical , Stocks , Technicals

DiaMedica Therapeutics Inc. (NASDAQ:DMAC) Short Interest Up 55.6% in March

DiaMedica Therapeutics Inc. (NASDAQ:DMAC – Get Rating) was the recipient of a large increase in short interest during the month of March. As of March 31st, there was short interest totalling 91,500 shares, an increase of 55.6% from the March 15th total of 58,800 shares. Based on an average daily trading volume, of 31,800 shares, […]

Davidj-wambeke , Citadel-advisors , Dimensional-fund-advisors , Diamedica-therapeutics-inc , Renaissance-technologies , Diamedica-therapeutics-company-profile , Nasdaq , Diamedica-therapeutics , Get-rating , Medica-therapeutics-trading-down , Medica-therapeutics

DiaMedica Therapeutics (NASDAQ:DMAC) Posts Quarterly Earnings Results

DiaMedica Therapeutics (NASDAQ:DMAC – Get Rating) posted its quarterly earnings results on Tuesday. The company reported ($0.14) EPS for the quarter, hitting the consensus estimate of ($0.14), Yahoo Finance reports. During the same quarter in the previous year, the company earned ($0.10) EPS. DiaMedica Therapeutics Stock Performance DMAC stock opened at $1.52 on Wednesday. The […]

Dimensional-fund-advisors , Citadel-advisors , Renaissance-technologies , Yahoo , Diamedica-therapeutics-company-profile , Diamedica-therapeutics-inc , Diamedica-therapeutics , Get-rating , Yahoo-finance , Medica-therapeutics , Street-group

DiaMedica Therapeutics (DMAC) Set to Announce Earnings on Tuesday

DiaMedica Therapeutics (NASDAQ:DMAC – Get Rating) is scheduled to post its quarterly earnings results after the market closes on Tuesday, March 28th. Analysts expect DiaMedica Therapeutics to post earnings of ($0.14) per share for the quarter. Individual that wish to register for the company’s earnings conference call can do so using this link. DiaMedica Therapeutics […]

Dimensional-fund-advisors , Diamedica-therapeutics-company-profile , Renaissance-technologies , Citadel-advisors , Diamedica-therapeutics-inc , Diamedica-therapeutics , Get-rating , Medica-therapeutics , Fund-advisors , Street-corp , Jane-street-group